Y-mAbs Therapeutics Stock (NASDAQ: YMAB) stock price, news, charts, stock research, profile.
Open | $12.960 |
Close | - |
Volume / Avg. | 44.596K / 388.615K |
Day Range | 12.060 - 12.960 |
52 Wk Range | 4.600 - 20.900 |
Market Cap | $541.608M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 34 |
Short Interest | 6.39% |
Days to Cover | 7.12 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Y-mAbs Therapeutics (NASDAQ: YMAB) through any online brokerage.
Other companies in Y-mAbs Therapeutics’s space includes: Cabaletta Bio (NASDAQ:CABA), KalVista Pharma (NASDAQ:KALV), Humacyte (NASDAQ:HUMA), Celcuity (NASDAQ:CELC) and Korro Bio (NASDAQ:KRRO).
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by HC Wainwright & Co. on Wednesday, March 6, 2024. The analyst firm set a price target for 22.00 expecting YMAB to rise to within 12 months (a possible 28.96% upside). 11 analyst firms have reported ratings in the last year.
The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $17.06 last updated May 8, 2024 at 7:28 AM EDT.
There are no upcoming dividends for Y-mAbs Therapeutics.
Y-mAbs Therapeutics’s Q2 earnings are confirmed for Thursday, August 8, 2024.
There is no upcoming split for Y-mAbs Therapeutics.
Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.